Luminex (LMNX) Stock Price, News & Analysis

Company Overview

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

Key Stats

• Today's Range: $36.99 to $36.99
• 50-Day Range: $36.66 to $37.01
• 52-Week Range: $20.61 to $41.69
• Volume: N/A
• Average Volume: 873,093 shs
• Market Capitalization: $1.75 billion
• P/E Ratio: 72.53
• Dividend Yield: 1.08%
• Price Target: N/A
• Consensus Rating: N/A

LMNX Stock Analysis - Frequently Asked Questions

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) released its quarterly earnings results on Sunday, February, 7th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.13 by $0.12. Luminex's quarterly revenue was up 23.1% on a year-over-year basis.
Read the conference call transcript.

What other stocks do shareholders of Luminex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Luminex investors own include Bristol-Myers Squibb (BMY), Intel (INTC), Micron Technology (MU), Cisco Systems (CSCO), NVIDIA (NVDA), Pfizer (PFE) and QUALCOMM (QCOM).

Company Calendar

• Last Earnings: 2/07/2021
• Today: 11/21/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & Medical Instruments
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:LMNX
• CUSIP: 55027E10
• CIK: 1033905
• Web: www.luminexcorp.com
• Phone: 512-219-8020
• Fax: N/A
• Employees: 1,325
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.32
• Trailing P/E Ratio: 72.53
• Forward P/E Ratio: 39.35
• P/E Growth: N/A
• Net Income: $15.17 million
• Net Margins: 5.39%
• Pretax Margin: N/A
• Return on Equity: 4.66%
• Return on Assets: 2.91%

Debt

• Debt-to-Equity Ratio: 0.52
• Current Ratio: 8.37
• Quick Ratio: 6.08

Sales & Book Value

• Annual Sales: $417.40 million
• Price / Sales: 4.19
• Cash Flow: $1.12 per share
• Price / Cash Flow: 32.98
• Book Value: $11.13 per share
• Price / Book: 3.32

Miscellaneous

• Outstanding Shares: 47,314,000
• Free Float: N/A
• Market Cap: $1.75 billion
• Optionable: Optionable
• Beta: 0.56